Major pharmaceutical firms Moderna and Merck promote new mRNA cancer vaccine to stop melanoma from coming back.
Two pharmaceutical companies based in the U.S. have reported encouraging results from a “Phase 3 clinical trial” indicating that a personalized mRNA cancer vaccine can enhance patient outcomes when combined with standard immunotherapy for those with high-risk melanoma. This experimental treatment, known as intismeran autogene (mRNA-4157/V940), was jointly developed by Moderna and Merck. It achieved […]
Pharmaceutical Companies Aim to Transform Toad Venom into a Successful Medication
Psychedelic Venom: A New Frontier for Big Pharma Major pharmaceutical companies are making a bold gamble, aiming to transform toad psychedelic venom into a lucrative product. They are investing billions in a drug known as 5-MeO-DMT, commonly referred to as Bufo. This potent psychedelic occurs naturally in the venom of Colorado River toads. Its rising […]
Trump targets international pharmaceutical companies in major announcement
Significant Changes Expected in Generic Drug Pricing Recent tariff announcements from President Donald Trump may lead to big shifts in the pricing of generic drugs. In a post on Truth Social, Trump indicated that generic drug imports would initially enjoy a zero tariff for two years, followed by two major tariff increases thereafter. The president […]
The incredible medications from big pharmaceutical companies come with an unpleasant drawback.
Living with my husband, who has bipolar disorder, I’ve seen how effective his medications can be. They not only enhance his life but also contribute to the well-being of our family. I’m thankful for the advancements from pharmaceutical companies that help sustain family bonds. Still, my trust in Big Pharma is, well, complicated. The reality […]
Trump Reaches Agreement with Regeneron: 17th Pharmaceutical Agreement Since Autumn
Trump Announces Deal for Regeneron’s Drug Pricing WASHINGTON—President Donald Trump has revealed a new agreement that will implement most-favored-nation pricing for Regeneron’s latest medication within state Medicaid systems. This marks the 17th such deal he has established with a major pharmaceutical company since earlier this fall. A fact sheet from the White House outlines that […]
Want to reach 100 years old? Don’t count on the pharmaceutical industry for assistance.
Reflections on the Medical System A few years back, I went through a severe accident that left me with significant injuries. My recovery—thanks to surgery and medication—was something I truly appreciated. After enduring eight broken ribs, five fractured collarbones, and a collapsed lung, I managed to return to work just a few months later, which […]
Pharmaceutical companies AbbVie and Genentech partner with TrumpRx Hub for the administration’s ‘Most-Favored-Nation’ pricing plan.
TrumpRx Launches Discounted Prescription Drugs Recently, two significant pharmaceutical companies have joined the effort to provide discounted medications at White House stores. TrumpRx, an initiative aimed at making prescription drugs more affordable, has seen participating companies expand. In line with the administration’s Most Favored Nation (MFN) program, AbbVie and Genentech are now offering their prescription […]
Trump signs order to enforce 100% tariff on brand-name medications — pharmaceutical industry responds
Trump’s Executive Order on Drug Tariffs President Donald Trump recently announced a new executive order aimed at implementing tariffs on branded medications, with the intention of reducing the United States’ reliance on drug imports. In his statement, the president expressed that these tariffs, which will reach as high as 100%, are necessary for national security […]
$400 Billion in Pharmaceutical Production Returning to the U.S.
Commerce Secretary Discusses Drug Manufacturing Shift to the U.S. During a recent policy forum organized by Breitbart News, Commerce Secretary Howard Lutnick shared insights that $400 billion in drug manufacturing is set to return to the United States, largely due to policies from the Trump administration. “We’re aiming to provide more affordable medications in America, […]
AI company Tempus secures $1.1 billion in data agreements with leading pharmaceutical firms
Tempus AI Reports Record Growth and Customer Engagement 2026/01/11 – 5:30 PM Tempus AI, Inc. has shared preliminary, unaudited data showcasing a substantial revenue of approximately $316 million for the year 2025. This marks a 31% increase from the previous year, driven notably by a 38% growth in their Insight (data license) segment. The net […]